Renovo revises Juvista deal with Shire to regain RoW rights
This article was originally published in Scrip
Renovo has revised its licensing deal with Shire for Juvista, and now has the rights to sell and license the wound healing product in all territories other than the US, Mexico and Canada.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.